An Insmed drug developed for a serious chronic lung disorder with no FDA-approved therapies handily beat a placebo in a pivotal clinical trial, preliminary results that set the stage for a regulatory ...

Please provide your email address to receive an email when new articles are posted on . New endpoints from the ASPEN trial were presented at the World Bronchiectasis Conference. FDA new drug ...

Please provide your email address to receive an email when new articles are posted on . Brensocatib given as 10 mg or 25 mg performed better than placebo for three outcomes related to pulmonary ...

If you’re living with bronchiectasis, you’re likely familiar with the exhausting cycle of thick mucus, chronic coughing, and fear of the next flare-up. For years, treatment has focused on managing ...

CEO Will Lewis highlighted the strong start to 2025, driven by double-digit year-over-year revenue growth for ARIKAYCE and progress in mid to late-stage clinical programs. The FDA's review of the NDA ...

CEO Will Lewis highlighted 2024 as a transformative year for Insmed, driven by successful clinical and commercial milestones. Key achievements included positive Phase 3 ASPEN data for brensocatib in ...